Background: Tongue squamous cell carcinoma (TSCC) is the second most common malignancy in oral carcinoma. lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was regarded as an oncogenic factor in various carcinomas. However, its underlying molecular mechanisms in the development and progression of TSCC have not been well featured till now. Methods: The expressions of MALAT1, miR-140-5p and p21 (RAC1)-activated kinase 1 (PAK1) mRNA were measured by RT-qPCR assay. The protein level of PAK1 was determined by western blot analysis. Cell viability was detected by Cell Counting Kit-8 assay. Transwell chamber was used to detect cell migratory and invasive capability. Luciferase reporter assay, RNA-binding protein immunoprecipitation (RIP) assay and biotin pull-down assay were applied to evaluate the relationship between MALAT1, miR-140-5p and PAK1. Xenograft experiments were performed to assess the effect and mechanism of MALAT1 in TSCC tumor growth. Results: The expression of MALAT1 and p21 (RAC1)-activated kinase 1 (PAK1) was upregulated and microRNA-140-5p (miR-140-5p) expression was downregulated in TSCC tissues and cells. MALAT1 knockdown induced miR-140-5p expression by direct interaction. Moreover, MALAT1 knockdown inhibited proliferation, migration, and invasion by upregulating miR-140-5p expression in TSCC cells. Additionally, PAK1 was identified as a direct target of miR-140-5p. Also, MALAT1 knockdown inhibited PAK1 expression by upregulating miR-140-5p in TSCC cells. Furthermore, miR-140-5p overexpression curbed the proliferation, migration, and invasion of TSCC cells by targeting PAK1. Finally, MALAT1 knockdown inhibited tumor growth by upregulating miR-140-5p and downregulating PAK1 in mouse xenograft models of TSCC. Conclusion: MALAT1 contributed to TSCC progression via miR-140-5p-PAK1 regulatory axis, highlighting a potential target for TSCC management.
Introduction
Tongue squamous cell carcinoma (TSCC), the second most common oral malignancy, was responsible for ~30% of all newly diagnosed oral carcinomas in the USA in 2018. 1 In China, the incidence rate of oral carcinoma is ~4.81% and the mortality rate is about 2.21% in all carcinomas. 2 Moreover, the 5-year survival rate of TSCC patients has shown no obvious improvement over the past decades, while the incidence is gradually increasing in young people. 3 Despite the great advances in diagnosis and therapy of TSCC, 4, 5 it is still necessary to clarify the molecular mechanisms underlying TSCC pathogenesis in order to identify more effective interventions.
lncRNAs, a group of transcripts longer than 200 nucleotides (nt) without proteincoding potential, have been well documented as critical players in the development and submit your manuscript | www.dovepress.com
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Zhu et al progression of carcinomas including TSCC. 6, 7 Metastasisassociated lung adenocarcinoma transcript 1 (MALAT1), an lncRNA located at chromosome 11q13, was first identified as a prognostic marker in non-small-cell lung carcinoma. 8 Recently, MALAT1 has been found to be implicated in tumorigenesis and progression of a great variety of carcinomas. 9, 10 Moreover, some researchers have provided evidence of MALAT1 as a biomarker and prognostic indicator in human carcinomas. 11, 12 For instance, MALAT1 facilitated cell epithelial-mesenchymal transition (EMT) and suppressed apoptosis by regulating Wnt/β-catenin signaling in TSCC. 13 Knockdown of MALAT1 resulted in the upregulation of small proline-rich proteins, thereby impairing the proliferative and migratory capacities of TSCC cells.
14 MALAT1 promoted EMT-mediated metastasis in oral squamous cell carcinoma (OSCC) through activating β-catenin and NF-κB pathways. 15 However, the molecular mechanisms of MALAT1 in the development and progression of TSCC have not been thoroughly elucidated.
miRNAs, a class of endogenous small non-coding RNAs about 22 nt long, can regulate the translation and stability of mRNAs at post-transcriptional levels. 16 Emerging evidence shows that miRNAs can act as potential oncogenic factors or tumor suppressors in human carcinomas by regulating the processes associated with tumorigenesis, such as inflammation, cell cycle, stress response, differentiation, apoptosis, and invasion. 17 miR-140-5p has been reported as an antitumor factor in multiple carcinomas, such as gastric carcinoma, 18 hepatocellular carcinoma, 19 lung carcinoma, 20 and ovarian carcinoma. 21 Moreover, Kai et al pointed out that miR-140-5p could suppress cell migration and invasion in TSCC. 22 In the present study, it is demonstrated that MALAT1 expression was upregulated and miR-140-5p expression was downregulated in TSCC tissues and cells. Further functional and mechanism analysis demonstrated that MALAT1 promoted the development of TSCC by miR-140-5p/p21 (RAC1)-activated kinase 1 (PAK1) regulatory pathway in vitro and in vivo.
Materials and methods
Tissue samples
TSCC tissues and adjacent normal tissues were obtained from 40 patients diagnosed with TSCC between January 2014 and December 2016 at our hospital. All tissues were immediately frozen in liquid nitrogen during the surgical procedure. The study was approved by the Ethics Committee of Changhai Hospital, Second Military Medical University. All patients signed the written informed consents prior to enrolling in this study. This study was conducted in accordance with the Declaration of Helsinki.
cell culture
Primary normal human oral keratinocytes (NHOKs) were isolated from keratinized oral epithelial tissues of patients who suffered from flap operation to remove impacted wisdom teeth. This experiment was carried out with the written informed consents from the patients and the approval of Ethics Committee of Changhai Hospital. NHOKs were cultured in Defined Keratinocyte-serum-free medium (Thermo Fisher Scientific, Waltham, MA, USA). Human TSCC cell lines (Tca8113, SCC-2, SCC-4, SCC-9, and Cal-27) were purchased from BeNa Culture Collection (Beijing, China) and incubated in Roswell Park Memorial Institute (RPMI) 1640 medium (Thermo Fisher Scientific) supplemented with 10% FBS (Thermo Fisher Scientific). All cells were grown in a humidified incubator containing 5% CO 2 at 37°C.
cell transfection
siRNA targeting MALAT1 (si-MALAT1), scrambled control siRNA (si-NC), miR-140-5p mimics, miRNA control (miR-NC), miR-140-5p inhibitor (anti-miR-140-5p) and its control anti-miR-NC were synthesized by GenePharma Co., Ltd (Shanghai, China). To construct MALAT1 or PAK1 overexpression plasmid, the full-length sequences of MALAT1 or PAK1 were amplified by PCR and then subcloned into pcDNA3.1 vector (Thermo Fisher Scientific), named as pcDNA3.1-MALAT1 (MALAT1) and pcDNA3.1-PAK1 (PAK1). All these plasmids and oligonucleotides were transfected into TSCC cells by Lipofectamine 2000 reagent (Thermo Fisher Scientific) according to the manufacturer's instructions.
Quantitative reverse transcriptase Pcr (rT-qPcr) assay
Total RNA was extracted from TSCC tissues and cells by TRIzol reagent (Thermo Fisher Scientific) following the manufacturer's protocols. For the expression analysis of MALAT1, an equal amount of RNA (1 µg) was reverse transcribed into cDNA first strand using M-MLV reverse transcriptase (Promega, Madison, WI, USA), followed by quantitative analysis using FastStart Universal SYBR Green Master (Roche Diagnostics, Mannheim, Germany) with GAPDH as the internal reference. The expression analysis of miR-140-5p was performed by the S-Poly(T) method. Briefly, RNA was first polyadenylated using Poly(A) Polymerase Tailing Kit (Epicenter, Madison, WI, USA), followed by the reverse transcription with M-MLV High-Performance Reverse Transcriptase (Epicenter) via miR-140-5p-RT primer. At last, the expression level of miR-140-5p was detected by miR-140-5p primers (forward and reverse) and Taqman probe with small nucleolar RNA SNORD47 as an endogenous control. ) in serum-free RPMI 1640 medium were inoculated into the upper chambers, while medium with 10% FBS was added to the lower chambers. After 48 hours of incubation at 37°C, cells on the upper side of the membranes were removed using a cotton swab. Cells adhering to the lower surface were photographed and counted after fixing with 100% pre-cold methanol and staining using 0.1% crystal violet solution. For cell invasion assay, the same experimental procedures were performed, except that the Transwell chambers were precoated with Matrigel (BD Biosciences).
Western blot assay
Total protein was obtained from TSCC Cells using pre-cold RIPA lysis buffer (Sigma-Aldrich, St Louis, MO, USA) containing protease inhibitor cocktail (Roche Diagnostics). An equal amount of protein (40 µg per lane) was separated by 10% SDS-PAGE gel and transferred to nitrocellulose membrane (EMD Millipore, Billerica, MA, USA). After blocking with 5% skimmed milk for 1 hour at room temperature, the membranes were incubated with primary antibody against PAK1 or β-actin (Abcam, Cambridge, UK) overnight at 4°C. Subsequently, the membranes were further probed with appropriate HRPconjugated secondary antibody for 1 hour at room temperature. Finally, the protein signals were measured by BeyoECL Plus (Beyotime, Shanghai, China) and quantified with ImageJ software. The experiment was repeated three times.
Bioinformatics analysis
The potential miRNAs that have a chance to interact with MALAT1 were predicted by miRcode database (http://www.mircode.org/). The candidate target mRNAs of miR-140-5p were predicted using the miRcode (http://www.mircode.org/) and miRwalk (http://mirwalk.umm.uni-heidelberg.de/) databases.
luciferase reporter assay
The fragments of MALAT1 and PAK1-3′UTR region containing putative miR-140-5p binding sites were amplified by PCR and constructed into pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega), named as MALAT1-WT and PAK1-3′UTR-WT reporter, respectively. QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) was used to generate MALAT1-MUT and PAK1-3′UTR-MUT reporters containing mutant miR-140-5p binding sites. Then, the constructed luciferase reporters were, respectively, co-transfected with miR-NC or miR-140-5p mimic into TSCC cells. At 48 hours after transfection, luciferase activity was detected with Dual-Luciferase Reporter Assay System (Promega) referring to the manufacturer's instructions.
rna-binding protein immunoprecipitation (riP) assay
The RIP assay was performed using the EZ-Magna RIP Kit (EMD Millipore), referring to the instructions of the manufacturer. Briefly, TSCC cells were lysed by RIP lysis buffer supplemented with cocktail (Roche Diagnostics). Then, cell supernatants were incubated overnight at 4°C with primary antibody against Ago2 or mouse IgG (EMD Millipore) and protein A/G magnetic beads. Following this, RNase-free DNase I (Promega) and Proteinase K were used to digest extra DNAs and proteins. At last, purified RNA was analyzed by the RT-qPCR assay to measure the expression of MALAT1 and miR-140-5p.
Biotin pull-down assay
The pull-down assay was performed according to a previous report. 23 Briefly, Tca8113 cells were transfected with biotinylated MALAT1 probe (Bio-MALAT1-probe) or a negative control probe (Bio-NC-probe). At 48 hours after transfection, cells were harvested for biotin-based pull-down assay, followed by RT-qPCR assay to determine miR-140-5p level.
animal experiments
The animal experiments were performed with the approval of the Ethics Committee of Changhai Hospital, Second Military Medical University. Animal experiments were carried out according to the National Institutes of Health guidelines to the Care and Use of Laboratory Animals. Female Nu/Nu nude mice (6-8 weeks old, n=12) were purchased from Shanghai SLAC Laboratory Animal Co., Ltd (Shanghai, China). Lentiviruses carrying MALAT1 shRNA (sh-MALAT1) or control shRNA (sh-NC) were purchased from Genomeditech Co., Ltd (Shanghai, China) and then added into Tca8113 cells. Next, Tca8113 cells (5×10 6 )
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Zhu et al infected with lentiviruses carrying sh-NC or sh-MALAT1 were injected subcutaneously into the right flanks of sh-NC or sh-MALAT group mice with six mice in each group. Tumor volume was monitored using a caliper every week with the formula: volume = (long diameter × short diameter 2 )/2. Tumors were resected, photographed, and weighed at 5 weeks after injection. The levels of MALAT1 and miR-140-5p were measured by RT-qPCR assay in resected xenograft tumors at the end of experiments. PAK1 protein level in xenograft tumors was determined by Western blot assay at the end of experiments.
statistical analysis
Results were presented as mean ± SD from at least three independent experiments. Student's t-test/Wilcoxon test (for two-group data) or one-way ANOVA together with Tukey's post hoc test (for more than two-group data) was used for the analysis of differences. The correlation between miR-140-5p and MALAT1 or PAK1 was evaluated by Pearson correlation analyses. P,0.05 represented the difference was statistically significant.
Results
MALAT1 expression was upregulated and miR-140-5p expression was downregulated in Tscc tissues and cells
First, the expression patterns of MALAT1 and miR-140-5p were investigated in TSCC tissue specimens and cell lines by RT-qPCR assay. Results showed that MALAT1 expression was markedly increased ( Figure 1A ) and miR-140-5p expression was strikingly decreased ( Figure 1B ) in TSCC tissues compared with adjacent non-carcinomatous tissues. Moreover, MALAT1 expression was found to be associated with tumor size, lymph node metastasis (LNM), and TNM stage in TSCC (Table 1) . Correlation coefficient analysis also showed that miR-140-5p level was inversely associated with MALAT1 level in TSCC tissues ( Figure 1C ). Moreover, RTqPCR assay showed that MALAT1 expression was remarkably upregulated ( Figure 1D ) and miR-140-5p expression was notably downregulated ( Figure 1E ) in TSCC cell lines (Tca8113, SCC-2, SCC-4, SCC-9, and Cal-27) compared with NHOK cell line. In summary, these data indicated 
MALAT1 inhibited miR-140-5p expression by direct interaction
Accumulating evidence reveals that lncRNAs can serve as miRNA sponges or decoys to modulate endogenous miRNAs, thus leading to derepression of target mRNAs. 24 Thus, whether MALAT1 could act as a miR-140-5p sponge to exert its oncogenic effects was further explored in TSCC. Bioinformatics analysis by miRcode website showed that there were several complementary sites between MALAT1 and miR-140-5p (Figure 2A ). Dual-luciferase reporter assay proved that the overexpression of miR-140-5p markedly attenuated luciferase activity of MALAT1-WT reporter, but not that of MALAT1-MUT reporter in Tca8113 cells ( Figure 2B ). RIP assay further revealed that both MALAT1 and miR-140-5p were remarkably enriched by Ago2 antibody in Tca8113 cells compared with anti-IgG negative control group ( Figure 2C ). Subsequent pull-down assay demonstrated that biotin-labeled MALAT1 probe (Bio-MALAT1-probe) could substantially enrich miR-140-5p in Tca8113 cells compared with the control group ( Figure 2D) . Moreover, MALAT1 expression was reduced ( Figure 2E ) and miR-140-5p expression was enhanced ( Figure 2F ) in Tca8113 and SCC-9 cells transfected with si-MALAT1. That is to say, MALAT1 knockdown promoted miR-140-5p expression via direct interaction in TSCC cells.
MALAT1 knockdown suppressed the proliferation, migration, and invasion by regulating miR-140-5p in Tscc cells
First, the transfection efficiency of miR-140-5p inhibitor in TSCC cells was confirmed. As presented in Figure 3A and B, a notable decrease in miR-140-5p expression was observed in Tca8113 and SCC-9 cells compared with untransfected group or anti-miR-NC group. Then, the effects of MALAT1 on the proliferation, migration, and invasion of TSCC cells were detected by CCK-8, Transwell migration, and invasion assay. The results showed that downregulation of MALAT1 by si-MALAT1 significantly suppressed the proliferation ( Figure 3C and D) , migration ( Figure 3E ), and invasion ( Figure 3F ) in both Tca8113 and SCC-9 cells. To further investigate whether the effects of MALAT1 in TSCC progression were mediated by miR-140-5p, miR-140-5p inhibitor was introduced into si-MALATA-transfected TSCC cells. The results showed that si-MALATA-induced inhibition of proliferation ( Figure 3C and D), migration ( Figure 3E ), and invasion ( Figure 3F ) was greatly attenuated by knockdown of miR-140-5p. Taken together, these data indicate that MALAT1 exerted its oncogenic effects partially through suppressing miR-140-5p expression.
MALAT1 knockdown suppressed PaK1 expression by upregulating miR-140-5p
It is well known that miRNAs exert their functions by modulating the expression of target genes. By using miRcode website, the complementary sequences between miR-140-5p and PAK1 3′UTR were identified ( Figure 4A ). Subsequent dualluciferase reporter assay showed that miR-140-5p overexpression decreased the luciferase activity of PAK1-WT reporter, while little change was observed in the luciferase activity of PAK1-MUT reporter between miR-NC and miR-140-5p groups ( Figure 4B ). To explore the effect of miR-140-5p on PAK1 expression, miR-140-5p mimic was transfected into TSCC cells. As expected, transfection of miR-140-5p mimic resulted in an obvious elevation of miR-140-5p level in Tca8113 and SCC-9 cells ( Figure 4C ). Western blot analysis revealed that the ectopic expression of miR-140-5p dramatically suppressed PAK1 protein expression in Tca8113 and SCC-9 cells ( Figure 4D ). PAK1 expression was found to be markedly upregulated in six randomly selected TSCC tissues compared with corresponding normal tissues ( Figure 4E ). Moreover, a notable upregulation of PAK1 mRNA level was observed in 40 cases of TSCC tissues compared with normal tissues ( Figure 4F ). Additionally, PAK1 mRNA level was 
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Zhu et al markedly increased in several TSCC cells (Tca8113, SCC-2, SCC-4, SCC-9, and Cal-27) compared with NHOK control cells ( Figure 4G ). Subsequent correlation analysis revealed that PAK1 mRNA level was negatively associated with PAK1 level in TSCC tissues ( Figure 4H ). Furthermore, MALAT1 knockdown resulted in a prominent decline of PAK1 protein expression in both Tca8113 and SCC-9 cells, while this effect was markedly weakened by miR-140-5p inhibitor ( Figure 4I ). Overall, these data indicate that MALAT1 could act as a molecular sponge of miR-140-5p to sequester miR-140-5p from its target gene PAK1, resulting in the upregulation of PAK1 level in TSCC cells.
miR-140-5p repressed the proliferation, migration, and invasion through targeting PaK1 in Tscc cells
To further explore whether miR-140-5p affected TSCC development by regulating PAK1, the transfection efficiency of PAK1 overexpression plasmid (pcDNA3.1-PAK1) was first investigated in TSCC cells. As displayed in Figure 5A and B, Figure 5A and B) , suggesting its applicable values in subsequent gain-of-function experiments. Then, TSCC cells were co-transfected with miR-140-5p mimics and pcDNA3.1-PAK1. Results showed that miR-140-5p overexpression led to a significant decrease in proliferation, migration, and invasion of Tca8113 and SCC-9 cells, while these effects were substantially abated following increase of PAK1 expression ( Figure 5C-F) . All these data suggest that miR-140-5p suppressed the proliferation, migration, and invasion via downregulating PAK1 in TSCC cells.
MALAT1 knockdown inhibited the growth of Tscc xenograft tumors through upregulating miR-140-5p and downregulating PaK1 in vivo
First, MALAT1 expression level was measured in Tca8113 cells infected with sh-NC or sh-MALAT1 lentiviruses. 
Discussion
Accumulating evidence indicates that abnormal expression of lncRNAs and miRNAs is closely associated with the development and progression of human carcinomas. 25 Moreover, some reports pointed out that lncRNAs could act as potential tumor suppressors or oncogenic factors in TSCC. For instance, lncRNA AFAP1 antisense RNA 1 (AFAP1-AS1) facilitated proliferation, migration, and invasion via activating Wnt/β-catenin pathway in TSCC cells. 26 NKILA impaired cell migratory and invasive capacities by inhibiting EMT via regulation of NF-κB activity in TSCC. 27 Moreover, the carcinogenic effects of MALAT1 on TSCC have been highlighted in several reports. 14, 28 Nevertheless, the underlying molecular mechanisms of MALAT1 in TSCC progression are far from being elucidated.
A growing body of literature points out that lncRNAs can serve as miRNA decoys or sponges to affect their expression. 29 miR-140-5p has been found to inhibit cell migration and invasion in TSCC. 22 Moreover, previous studies showed that MALAT1 promoted proliferation and invasion of uveal melanoma cells through silencing miR-140, 30 and MALAT1 knockdown enhanced the blood-tumor barrier permeability by increasing miR-140 expression. 31 In the present study, it is found that MALAT1 expression was markedly upregulated in TSCC tissues and cells. Moreover, MALAT1 expression was associated with tumor size, LNM, and TNM stage in TSCC. Consistently, Fang et al pointed out that TSCC patients (n=59) with LNM have higher MALAT1 expression compared with patients without LNM (n=68). 14 Zhou et al disclosed that OSCC patients (n=19) with higher MALAT1 expression have a shorter survival time compared with patients with lower MALAT1 expression (n=35). 15 Also, miR-140-5p expression was notably downregulated in TSCC tissues and cells. Moreover, there existed a significant inverse correlation between MALAT1 and miR-140-5p expression in TSCC tissues. Subsequent bioinformatics analysis showed that MALAT1 contained binding sequences of miR-140-5p. Luciferase reporter experiments, RIP, and pull-down assay further validated the interplay between MALAT1 and miR-140-5p. Furthermore, MALAT1 cells, whereas these effects were dramatically reversed after overexpressing PAK1, suggesting that the tumor-suppressive roles of miR-140-5p were mediated by PAK1. PAK1, a prototype of group I PAK family, has been elucidated as the cause for several oncogenic processes. 32, 33 Several documents verified that PAK1 was a vital target of miRNA signal pathways. For example, miR-494 repressed the proliferation, migration, and invasion of breast carcinoma cells by targeting PAK1. 34 miR-98 directly targeted the 3′UTR of PAK1 to downregulate its expression, thus inhibiting cell proliferation and invasion in non-small-cell lung carcinoma. 35 In this study, it is further demonstrated that MALAT1 knockdown inhibited the growth of TSCC xenograft tumors via upregulating miR-140-5p and downregulating PAK1 in vivo.
Previous studies showed that MALAT1 facilitated OSCC development by regulating miR-125b/signal transducer and activator of transcription 3 (STAT3) axis. 36 MALAT1 could interact with miR-320d by SRSF1, and miR-320d knockdown induced CCR7 expression in OSCC. 37 Moreover, Zhang et al pointed out that MALAT1 knockdown inhibited the tumorigenesis and progression of tongue cancer in vitro and in vivo by miR-124/jagged1 (JAG1) pathway.
28
MALAT1 could interact with miR-30a in human head and neck squamous cell carcinoma. 38 Moreover, some studies have shown that miR-124 could exert its antitumor effect by targeting STAT3 in hepatocellular carcinoma, 39 and that miR-140-5p suppressed glioma cell proliferation and invasion by targeting JAG1. 40 ADAM10, LAMC1, HDAC7, and PAX6 have been reported as the targets of miR-140-5p in tongue cancer. 22 Furthermore, Lee et al pointed out that PAK1 suppressed ADAM17 association and lipid raft transfer by phosphorylating paxillin, and HIV-1 and cancer cells could exploit a paxillin/integrin-controlled mechanism to release ADAM17/ADAM10-containing vesicles, hinting the link of PAK1 and ADAM10 (a target of miR-140-5p). 41 These data indicate that some downstream signaling pathways of MALAT1 were mutually relevant.
Moreover, bioinformatics analysis by miRcode website suggests that MALAT1 has a chance to interact with multiple miRNAs such as miR-503, miR-96, and miR-17-5p.
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Taken together, this study demonstrated that MALAT1 promoted the development of TSCC partly via regulating miR-140-5p/PAK1 pathway in vitro and in vivo. This study provides a novel insight into the involvement of MALAT1 in TSCC development and elucidates a promising therapeutic candidate for TSCC treatment.
